Skip to main content
SpringerLink
Log in
Book cover

Hodgkin Lymphoma pp 211–225Cite as

Pediatric Hodgkin Lymphoma

  • Chapter
  • First Online:

  • 1137 Accesses

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

Survival of a pediatric cancer patient is measured not only by the therapeutic eradication of the malignancy, but also by maintenance of potential for a life unburdened by medical morbidity. This challenge for pediatric Hodgkin lymphoma (HL) treatment has, in recent decades, defined the strategies of care. Although the biology and natural history of HL is similar in children and adults, pediatric treatment paradigms have been specifically designed to avoid the toxicities associated with the classic treatment approaches used for adults. This chapter highlights the impact of the tandem concerns for efficacy and safety on the evolution of treatment strategies for pediatric and adolescent HL. Although relapse is relatively uncommon, the efficacy and toxicity of salvage strategies impact on overall survival and quality of survival. Novel approaches designed initially for those with recurrent disease provide opportunity to explore new biologically based therapies. When applied to newly diagnosed patients, these new regimens may improve efficacy and reduce toxicity for all patients with HL.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    Mini-BEAM; BCNU, etoposide, cytarabine, melphalan

  2. 2.

    ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin; DHAP, dexamethasone, cytarabine, cisplatin; APPE, cytarabine, cisplatin, prednisone, etoposide; DECAL, cytarabine, cisplatin, prednisone, etoposide, asparaginase

  3. 3.

    EPIC, etoposide, vincristine epirubicin, prednisolone; IEP, ifosfamide, etoposide, prednisolone; ICE, ifosfamide, carboplatin, etoposide; IV, ifosfamide, vinorelbine

  4. 4.

    GV, gemcitabine, vinorelbine; IGEV, ifosfamide, gemcitabine, vinorelbine, prednisolone

References

  1. Hochberg J, Waxman IM, Kelly KM, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144:24–40.

    Article  PubMed  Google Scholar 

  2. Foltz LM, Song KW, Connors JM. Hodgkin’s lymphoma in adolescents. J Clin Oncol. 2006;24:2520–6.

    Article  PubMed  Google Scholar 

  3. Donaldson SS, Kaplan HS. Complications of treatment of Hodgkin’s disease in children. Cancer Treat Rep. 1982;66:977–89.

    PubMed  CAS  Google Scholar 

  4. Mauch PM, Weinstein H, Botnick L, et al. An evaluation of long-term survival and treatment complications in children with Hodgkin’s disease. Cancer. 1983;51:925–32.

    Article  PubMed  CAS  Google Scholar 

  5. Merchant TE, Nguyen L, Nguyen D, et al. Differential attenuation of clavicle growth after asymmetric mantle radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:556–61.

    Article  PubMed  Google Scholar 

  6. Probert JC, Parker BR, Kaplan HS. Growth retardation in children after megavoltage irradiation of the spine. Cancer. 1973;32:634–9.

    Article  PubMed  CAS  Google Scholar 

  7. Donaldson SS, Glatstein E, Rosenberg SA, Kaplan HS. Pediatric Hodgkin’s disease. II. Results of therapy. Cancer. 1976;37:2436–47.

    Article  PubMed  CAS  Google Scholar 

  8. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer. 1984;53:878–83.

    Article  PubMed  CAS  Google Scholar 

  9. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: Date from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–32.

    Article  PubMed  CAS  Google Scholar 

  10. Adams MJ, Hardenbergh PH, Constine LS, et al. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol. 2003;45:55–75.

    Article  PubMed  Google Scholar 

  11. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol. 1993;11:1208–15.

    PubMed  CAS  Google Scholar 

  12. Kung FH, Schwartz CL, Ferree CR, et al. POG 8625: a randomized trial comparing chemotherapy with chemoradiotherapy for children and adolescents with Stages I, IIA, IIIA1 Hodgkin Disease: a report from the Children’s Oncology Group. J Pediatr Hematol Oncol. 2006;28:362–8.

    Article  PubMed  CAS  Google Scholar 

  13. Weiner M, Leventhal B, Brecher M, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997;15:2769–79.

    PubMed  CAS  Google Scholar 

  14. Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114:2051–9.

    Article  PubMed  CAS  Google Scholar 

  15. Diehl V, Franlin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:2386–99.

    Article  PubMed  CAS  Google Scholar 

  16. Horning SJ, Hoppe RT, Breslin S, et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: Mature results of a prospective clinical trial. J Clin Oncol. 2002;20:630–7.

    Article  PubMed  Google Scholar 

  17. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin’s disease. N Engl J Med. 1990;322:7–13.

    Article  PubMed  CAS  Google Scholar 

  18. Mackie E, Radford M, Shalet S. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol. 1996;27:74–8.

    Article  PubMed  CAS  Google Scholar 

  19. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Rad Oncol Biol Phys. 1990;19:873–80.

    Article  CAS  Google Scholar 

  20. van den Berg H, Furstner F, van den Bos C, Behrendt H. Decreasing the number of MOPP courses reduces gonadal damage in survivors of childhood Hodgkin disease. Pediatr Blood Cancer. 2004;42:210–5.

    Article  PubMed  Google Scholar 

  21. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478–84.

    Article  PubMed  CAS  Google Scholar 

  22. Hunger S, Link M, Donaldson S. ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin’s disease: the Stanford experience. J Clin Oncol. 1994;12:2160–6.

    PubMed  CAS  Google Scholar 

  23. Bramswig J, Heimes U, Heiermann E, et al. The effects of different cumulative doses of chemotherapy on testicular function. Results in 75 patients treated for Hodgkin’s disease during childhood or adolescence. Cancer. 1990;65:1298–302.

    Article  PubMed  CAS  Google Scholar 

  24. Schellong G, Hornig I, Bramswig J, et al. Significance of procarbazine in the chemotherapy of Hodgkin’s disease–a report of the Cooperative Therapy Study DAL-HD-85. Klin Pädiatr. 1988;200:205–13.

    Article  PubMed  CAS  Google Scholar 

  25. Bonadonna G, Santoro A. ABVD chemotherapy in the treatment of Hodgkin’s disease. Cancer Treat Rev. 1982;9:21–35.

    Article  PubMed  CAS  Google Scholar 

  26. Doerffel W, Luders H, Ruhl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin’s disease in children and adolescents: analysis and outlook. Klin Padiatr. 2003;215:139–45.

    Article  Google Scholar 

  27. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin’s disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol. 2000;18:1500–7.

    PubMed  CAS  Google Scholar 

  28. Donaldson S, Hudson M, Lamborn K, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol. 2002;20:3081–7.

    Article  PubMed  CAS  Google Scholar 

  29. Tebbi CKMN, Schwartz C, Williams J, et al. Response dependent treatment of stages IA, IIA, and IIIA1 micro Hodgkin’s disease with ABVE and low dose involved field irradiation with or without dexrazoxane. Leuk Lymphoma. 2001;42:100.

    Google Scholar 

  30. Shahidi M, Kamangari N, Ashley S, et al. Site of relapse after chemotherapy alone for stage I and II Hodgkin’s disease. Radiother Oncol. 2006;78:1–5.

    Article  PubMed  Google Scholar 

  31. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol. 2006;79:270–7.

    Article  PubMed  Google Scholar 

  32. Nachman JB, Sposto R, Herzog P, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20:3765–71.

    Article  PubMed  Google Scholar 

  33. Korholz D, Claviez A, Hasenclever D, et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin’s disease: evolution in the tradition of the DAL/GPOH studies. Klin Pädiatr. 2004;216:150–6.

    Article  PubMed  CAS  Google Scholar 

  34. Korholz D, Kluge R, Wickmann L, et al. Importance of F18-fluorodeoxy-D-2-glucose positron emission tomography (FDG-PET) for staging and therapy control of Hodgkin’s lymphoma in childhood and adolescence – consequences for the GPOH-HD 2003 protocol. Onkologie. 2003;26:489–93.

    Article  PubMed  CAS  Google Scholar 

  35. Weiner MA, Leventhal BG, Marcus R, et al. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1991;9:1591–8.

    PubMed  CAS  Google Scholar 

  36. Friedmann AM, Hudson MM, Weinstein HJ, et al. Treatment of unfavorable childhood Hodgkin’s disease with VEPA and low-dose, involved-field radiation. J Clin Oncol. 2002;20:3088–94.

    Article  PubMed  CAS  Google Scholar 

  37. Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol. 1983;1:146–53.

    PubMed  CAS  Google Scholar 

  38. DeVita VT, Hubbard SM, Longo DL. Treatment of Hodgkin’s disease. J Natl Cancer Inst Monogr. 1990;10:19–28.

    Google Scholar 

  39. van Rijswijk RE, Haanen C, Dekker AW, et al. Dose intensity of MOPP chemotherapy and survival in Hodgkin’s disease. J Clin Oncol. 1989;7:1776–82.

    PubMed  Google Scholar 

  40. Kelly KM, Hutchinson RJ, Sposto R, et al. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: preliminary results from the Children’s Cancer Group Study CCG-59704. Ann Oncol. 2002;13 Suppl 1:107–11.

    Article  PubMed  Google Scholar 

  41. Mason DY, Banks PM, Chan J, et al. Nodular lymphocyte predominance Hodgkin’s disease: a distinct clinico-pathological entity. Am J Surg Pathol. 1994;18:526–30.

    Article  PubMed  CAS  Google Scholar 

  42. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin’s disease and lymphocyte-rich classical Hodgkin’s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin’s Disease. J Clin Oncol. 1999;17:776–83.

    PubMed  CAS  Google Scholar 

  43. Sandoval C, Venkateswaran L, Billups C, et al. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol. 2002;24:269–73.

    Article  PubMed  Google Scholar 

  44. Mauz-Korholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 2007;110:179–85.

    Article  PubMed  Google Scholar 

  45. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol. 2003;25:684–7.

    Article  PubMed  Google Scholar 

  46. Pellogrino B, Terrier-Lacobe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin’s lymphoma in children: therapeutic abstenstion after initial lymph node resection – A study of the French Society of Pediatric oncology. J Clin Oncol. 2003;21:2984–92.

    Google Scholar 

  47. Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children’s Cancer and Leukaemia Group report. Br J Haematol. 2007;138:761–8.

    Article  PubMed  CAS  Google Scholar 

  48. Miettinen M, Franssila KO, Saxen E. Hodgkin’s disease, lymphocyte predominance nodular: Increased risk of subsequent non-Hodgkin’s lymphoma. Cancer. 1983;51:2293–300.

    Article  PubMed  CAS  Google Scholar 

  49. Wickert RS, Weisenburger DD, Tierens A, et al. Clonal relationship between lymphocytic predominance Hodgkin’s disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood. 1995;86:2312–20.

    PubMed  CAS  Google Scholar 

  50. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26:434–9.

    Article  PubMed  Google Scholar 

  51. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood. 2005;105:4215–22.

    Article  PubMed  CAS  Google Scholar 

  52. Baker KS, Gordon BG, Grass TG, et al. Autologous hematopoetic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J Clin Oncol. 1999;17:825–31.

    PubMed  CAS  Google Scholar 

  53. Claviez A, Sureda A, Schmitz N. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2008;42 Suppl 2:S16–24.

    Article  PubMed  Google Scholar 

  54. Lieskovsky YE, Donaldson SS, Torres MA, et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin’s disease: results and prognostic indices. J Clin Oncol. 2004;22:4532–40.

    Article  PubMed  Google Scholar 

  55. Akhtar S, El Weshi A, Rahal M et al. (2009) High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin’s lymphoma. Bone Marrow Transplant. 2010 Mar;45(3):476-82. Epub 2009 Sep 7

    Google Scholar 

  56. Williams CD, Goldstone AH, Pearce R, et al. Autologous bone marrow transplantation for pediatric Hodgkin’s disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol. 1993;11:2243–9.

    PubMed  CAS  Google Scholar 

  57. Schellong G, Dorffel W, Claviez A, et al. Salvage therapy of progressive and recurrent Hodgkin’s disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol. 2005;23:6181–9.

    Article  PubMed  Google Scholar 

  58. Chen AR, Hutchison R, Hess A, et al. Clinical outcomes of patients with recurrent/refractory Hodgkin disease receiving cyclosporine, interferon-V and interleukin-2 immunotherapy to induce autoreactivity after autologous stem cell transplantation with BEAM: A COG study. Blood 2007;110:Abstract 1896.

    Google Scholar 

  59. Frankovich J, Donaldson SS, Lee Y, et al. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin’s disease: atopy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant. 2001;7:49–57.

    Article  PubMed  CAS  Google Scholar 

  60. Stoneham S, Ashley S, Pinkerton CR, et al. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol. 2004;26:740–5.

    Article  PubMed  Google Scholar 

  61. Bradley MB, Cairo MS. Stem cell transplantation for paediatric lymphoma: past, present and future. Bone Marrow Transplant. 2008;41:149–58.

    Article  PubMed  CAS  Google Scholar 

  62. Claviez A, Canals C, Dierickx D, et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood. 2009;114:2060–7.

    Article  PubMed  CAS  Google Scholar 

  63. Marina NM, Greenwald CA, Fairclough DL, et al. Serial pulmonary function studies in children treated for newly diagnosed Hodgkin’s disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine. Cancer. 1995;75:1706–11.

    Article  PubMed  CAS  Google Scholar 

  64. Mefferd JM, Donaldson SS, Link MP. Pediatric Hodgkin’s disease: pulmonary, cardiac, and thyroid function following combined modality therapy. Int J Radiat Oncol Biol Phys. 1989;16:679–85.

    Article  PubMed  CAS  Google Scholar 

  65. Green DM, Hall B. Pregnancy outcome following treatment during childhood or adolescence for Hodgkin’s disease. Pediatr Hematol Oncol. 1988;5:269–77.

    Article  PubMed  CAS  Google Scholar 

  66. Hudson MM, Poquette CA, Lee J, et al. Increased mortality after successful treatment for Hodgkin’s disease. J Clin Oncol. 1998;16:3592–600.

    PubMed  CAS  Google Scholar 

  67. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139–48.

    Article  PubMed  Google Scholar 

  68. Green DM, Hyland A, Chung CS, et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol. 1999;17:3207–15.

    PubMed  CAS  Google Scholar 

  69. Constine LS, Tarbell N, Hudson MM, et al. Subsequent malignancies in children treated for Hodgkin’s disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys. 2008;72:24–33.

    Article  PubMed  Google Scholar 

  70. Hodgson DC, Hudson MM, Constine LS. Pediatric hodgkin lymphoma: maximizing efficacy and minimizing toxicity. Semin Radiat Oncol. 2007;17:230–42.

    Article  PubMed  Google Scholar 

  71. Rubin P, Williams JP, Deveson SS, Travis LB, Constine LS. Semin Radiat Oncol. 2010 Jan 20(1):3-11..

    Google Scholar 

  72. Punnett A, Tsang R, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20(1):30–44.

    Article  PubMed  Google Scholar 

  73. Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1, 641 Hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol. 1996;14:1442–6.

    PubMed  CAS  Google Scholar 

  74. Rühl U, Albrecht M, Dieckmann K, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys. 2001;51:1209–18.

    Article  PubMed  Google Scholar 

  75. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin’s disease. J Clin Oncol. 2004;22:4541–50.

    Article  PubMed  CAS  Google Scholar 

  76. Oberlin O, Boilletot A, Leverger G, et al. Clinical staging, primary chemotherapy and involved-field radiotherapy in childhood Hodgkin’s disease. Eur Paediatr Oncol. 1985;2:65–70.

    Article  Google Scholar 

  77. Oberlin O, Leverger G, Pacquement M, et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin’s disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602–8.

    PubMed  CAS  Google Scholar 

  78. Schellong G. The balance between cure and late effects in childhood Hodgkin’s lymphoma: the experience of the German-Austrian Study-Group since 1978. Ann Oncol. 1996;7 Suppl 4:67–72.

    Article  PubMed  Google Scholar 

  79. Schellong G. Treatment of children and adolescents with Hodgkin’s disease: the experience of the German-Austrian Paediatric Study Group. Bailliere’s Clin Haematol. 1996;9:619–34.

    Article  CAS  Google Scholar 

  80. Shankar A, Ashley S, Radford M, et al. Does histology influence outcome in childhood Hodgkin’s disease? Results from the United Kingdom Children’s Cancer Study Group. J Clin Oncol. 1997;15:2622–30.

    PubMed  CAS  Google Scholar 

  81. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. Cancer. 1993;72:2049–57.

    Article  PubMed  CAS  Google Scholar 

  82. Atra A, Higgs E, Capra M, et al. ChlVPP chemotherapy in children with stage IV Hodgkin’s disease: results of the UKCCSG HD 8201 and HD 9201 studies. Br J Haematol. 2002;119:647–51.

    Article  PubMed  CAS  Google Scholar 

  83. Wolden SL, Lamborn KR, Cleary SF, et al. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol. 1998;16:536–44.

    PubMed  CAS  Google Scholar 

  84. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol. 2000;18:1492–9.

    PubMed  CAS  Google Scholar 

  85. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med. 1996;334:745–51.

    Article  PubMed  CAS  Google Scholar 

  86. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol. 2000;18:2435–43.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

With thanks to Ann Muhs, Rochester, for her help with the manuscript, particularly the references.

Author information

Authors and Affiliations

  1. Pediatric Haematology/Oncology Unit, John Radcliffe Hospital, Headley Way, Headington, Oxford, OX3 9DU, UK

    Georgina Hall

  2. Division of Pediatric Hematology/Oncology, Hasbro Children’s Hospital, 593 Eddy Street, Providence, RI, 02903, USA

    Cindy Schwartz

  3. Children & Young People’s Cancer Services, Divison of Paediatrics, University College Hospital, 250 Euston Road, London, NW1 1PQ, UK

    Stephen Daw

  4. University College Hospital London, London, UK

    Stephen Daw

  5. Department of Radiation oncology, University of Rochester Medical Center, Rochester, NY, USA

    Louis S. Constine

Authors
  1. Georgina Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen Daw
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louis S. Constine
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Georgina Hall .

Editor information

Editors and Affiliations

  1. Klinik I für Innere Medizin, Universität Köln, Joseph-Stelzmann-Str. 9, Köln, 50924, Germany

    Andreas Engert

  2. Dept. Medicine, Stanford University, Stanford, 94305-5479, California, USA

    Sandra J. Horning

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hall, G., Schwartz, C., Daw, S., Constine, L.S. (2011). Pediatric Hodgkin Lymphoma. In: Engert, A., Horning, S. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12780-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12780-9_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12779-3

  • Online ISBN: 978-3-642-12780-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation